Orexigen(R) Therapeutics to Speak at JMP Securities Healthcare Focus Conference

Oct 01, 2009, 08:01 ET from Orexigen Therapeutics, Inc.

SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the Fourth Annual JMP Securities Healthcare Focus Conference. The details are as follows:

    The Fourth Annual JMP Securities Healthcare Focus Conference
    Date:  October 5, 2009
    Time:  9:30am Eastern Time
    Location:  The New York Palace Hotel, New York
    Presentation Room:  Holmes II
    Speaker:  Michael Narachi, President and Chief Executive Officer

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave®, has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product, Empatic(TM), has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.

SOURCE Orexigen Therapeutics, Inc.



RELATED LINKS

http://www.Orexigen.com